SJS Investment Consulting’s Theravance Biopharma TBPH Stock Holding History

SJS Investment Consulting’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01K	Buy	+118	New	+$1.95K	﹤0.01%	1776

Other funds holding TBPH

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SJS Investment Consulting's TBPH Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 118 shares worth $2.01K. The stake represents ﹤0.01% of the portfolio and ranks #1776 among its holdings.

30 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

SJS Investment Consulting held 118 shares of Theravance Biopharma worth $2.01K as of Q2 2026.
Theravance Biopharma was a new SJS Investment Consulting position in Q2 2026.
Theravance Biopharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1776 holding.
30 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.